FIT Biotech Oy
Press release 17.10.2018 at 9.45 EET
FIT Biotech's cancer patent application published
FIT Biotech Oy ("Company", FITBIO: FN Finland) international patent application WO 2018/185110 has now been made public. If granted, the patent will ensure FIT Biotech the exclusive rights to commercialize its technology for the treatment of cancer.
The application is for utilizing the Company's proprietary GTU® and gtGTU® vectors for delivering therapeutic antibodies against cancer. This is in line with the Company's strategy to bring better, safer and more cost-efficient antibodies to a market that has been generally disappointed with the cost benefits seen by the entry of biosimilars.
CEO Erkki Pekkarinen comments: "This patent application is an important milestone in the development that we continue to do in our R&D portfolio. The biological therapeutics market continues to grow at an unprecedented pace and we are well positioned to meet the demand."
FIT BIOTECH OY
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
Principal media